Cargando…

The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era

INTRODUCTION: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tao, Ding, Songning, Huang, Rui, Wang, Hengxue, Wang, Junjun, Liu, Jiacheng, Wang, Jian, Li, Jie, Wu, Chao, Fan, Huafeng, Zhou, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186332/
https://www.ncbi.nlm.nih.gov/pubmed/35759239
http://dx.doi.org/10.1002/iid3.664
_version_ 1784724909214138368
author Ma, Tao
Ding, Songning
Huang, Rui
Wang, Hengxue
Wang, Junjun
Liu, Jiacheng
Wang, Jian
Li, Jie
Wu, Chao
Fan, Huafeng
Zhou, Nan
author_facet Ma, Tao
Ding, Songning
Huang, Rui
Wang, Hengxue
Wang, Junjun
Liu, Jiacheng
Wang, Jian
Li, Jie
Wu, Chao
Fan, Huafeng
Zhou, Nan
author_sort Ma, Tao
collection PubMed
description INTRODUCTION: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in the postvaccination era. METHODS: The epidemiology and clinical data of cases with confirmed SARS‐CoV‐2 Delta VOC infection were retrospective collected. Dates of the first positive PCR test were collected to estimate the distribution of latent period. RESULTS: Of the 40 patients, 16 were male (40%). The median age of patients was 47.5 years. The median latent period of patients was 6.0 days (interquartile range [IQR], 4.0−9.0 days) and the longest latent period was 13.0 days after exposure. The latent periods were longer in male patients compared to female patients (median, 8.5 days vs. 5.0 days, p = .041). The median latent period was comparable among fully vaccinated cases (6.5 days), no vaccinated cases (7.5 days), and partially vaccinated cases (5.5 days). CONCLUSIONS: The median latent period of SARS‐CoV‐2 Delta VOC infection was 6.0 days. The latent period between vaccinated and non‐vaccinated patients was not significantly different. The 14‐day quarantine program is sufficient to prevent the transmission of COVID‐19 by Delta VOC in the postvaccination era.
format Online
Article
Text
id pubmed-9186332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91863322022-06-14 The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era Ma, Tao Ding, Songning Huang, Rui Wang, Hengxue Wang, Junjun Liu, Jiacheng Wang, Jian Li, Jie Wu, Chao Fan, Huafeng Zhou, Nan Immun Inflamm Dis Short Reports INTRODUCTION: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in the postvaccination era. METHODS: The epidemiology and clinical data of cases with confirmed SARS‐CoV‐2 Delta VOC infection were retrospective collected. Dates of the first positive PCR test were collected to estimate the distribution of latent period. RESULTS: Of the 40 patients, 16 were male (40%). The median age of patients was 47.5 years. The median latent period of patients was 6.0 days (interquartile range [IQR], 4.0−9.0 days) and the longest latent period was 13.0 days after exposure. The latent periods were longer in male patients compared to female patients (median, 8.5 days vs. 5.0 days, p = .041). The median latent period was comparable among fully vaccinated cases (6.5 days), no vaccinated cases (7.5 days), and partially vaccinated cases (5.5 days). CONCLUSIONS: The median latent period of SARS‐CoV‐2 Delta VOC infection was 6.0 days. The latent period between vaccinated and non‐vaccinated patients was not significantly different. The 14‐day quarantine program is sufficient to prevent the transmission of COVID‐19 by Delta VOC in the postvaccination era. John Wiley and Sons Inc. 2022-06-10 /pmc/articles/PMC9186332/ /pubmed/35759239 http://dx.doi.org/10.1002/iid3.664 Text en © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Ma, Tao
Ding, Songning
Huang, Rui
Wang, Hengxue
Wang, Junjun
Liu, Jiacheng
Wang, Jian
Li, Jie
Wu, Chao
Fan, Huafeng
Zhou, Nan
The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
title The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
title_full The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
title_fullStr The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
title_full_unstemmed The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
title_short The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
title_sort latent period of coronavirus disease 2019 with sars‐cov‐2 b.1.617.2 delta variant of concern in the postvaccination era
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186332/
https://www.ncbi.nlm.nih.gov/pubmed/35759239
http://dx.doi.org/10.1002/iid3.664
work_keys_str_mv AT matao thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT dingsongning thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT huangrui thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wanghengxue thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wangjunjun thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT liujiacheng thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wangjian thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT lijie thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wuchao thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT fanhuafeng thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT zhounan thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT matao latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT dingsongning latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT huangrui latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wanghengxue latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wangjunjun latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT liujiacheng latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wangjian latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT lijie latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT wuchao latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT fanhuafeng latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera
AT zhounan latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera